

UNITED STATES PATENT AND TRADEMARK OFFICE

Cl.

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/078,808	02/19/2002	Manas Kumar Majumdar	08702.0086-00000	7146
22852 7	2590 06/22/2005		EXAMINER	
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER			ANDRES, JANET L	
LLP 901 NEW YORK AVENUE, NW		ART UNIT	PAPER NUMBER	
WASHINGTON, DC 20001-4413			1646	
		•	DATE MAILED: 06/22/2003	s ·

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/078,808	MAJUMDAR ET AL.				
Office Action Summary	Examiner	Art Unit				
	Janet L. Andres	1646				
The MAILING DATE of this communication Period for Reply	appears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR RETHE MAILING DATE OF THIS COMMUNICATIO - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a - If NO period for reply is specified above, the maximum statutory per - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the material patent term adjustment. See 37 CFR 1.704(b).	N. R 1.136(a). In no event, however, may a reply be time. reply within the statutory minimum of thirty (30) days id will apply and will expire SIX (6) MONTHS from atute, cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 1:	<u> 1 April 2005</u> .					
2a) This action is FINAL. 2b) ⊠ T	This action is FINAL . 2b)⊠ This action is non-final.					
•	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) ⊠ Claim(s) 21,23-29 and 31-37 is/are pending 4a) Of the above claim(s) is/are without 5) □ Claim(s) 21,23-29 and 31-37 is/are allowed 6) ⊠ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and	drawn from consideration.					
Application Papers		•				
9) The specification is objected to by the Example 10) The drawing(s) filed on is/are: a) and a Applicant may not request that any objection to the Replacement drawing sheet(s) including the conduction of the oath or declaration is objected to by the second se	accepted or b) objected to by the late the drawing(s) be held in abeyance. See rection is required if the drawing(s) is objected to by the late the drawing(s) is objected to by the late the la	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for fore a) All b) Some * c) None of: 1. Certified copies of the priority docum 2. Certified copies of the priority docum 3. Copies of the certified copies of the papplication from the International Bur * See the attached detailed Office action for a	ents have been received. ents have been received in Application of the properties of	on No ed in this National Stage				
Attachment(s)	· _					
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) 	4) 🔲 Interview Summary Paper No(s)/Mail Da					
Notice of Draitsperson's Fatent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/Paper No(s)/Mail Date		Patent Application (PTO-152)				

U.S. Patent and Trademark Office PTOL-326 (Rev. 1-04)

M

Art Unit: 1646

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 11 April 2005 has been entered. Claims 21, 23-29, and 31-37 are pending and under examination in this office action. The text of those sections of Title 35, U.S. Code, not included in this action can be found in a prior office action.

Claim Rejections Maintained/New Grounds of Rejection

2. The rejection of claims 21, 23-29, and 31 under 35 U.S.C. 102(a) as anticipated by WO 00/29552 or unpatentable over WO 00/29552 in view of the '819 patent is maintained for reasons of record in the previous office actions and applied to new claims 32-37.

Applicant's statement under 37 C.F.R. 1.131 is insufficient to overcome this rejection because it is not signed by all of the inventors. See MPEP §715.04:

The following parties may make an affidavit or declaration under 37 CFR 1.131:

- (A) All the inventors of the subject matter claimed.
- (B) An affidavit or declaration by less than all named inventors of an application is accepted where it is shown that less than all named inventors of an application invented the subject matter of the claim or claims under rejection. For example, one of two joint inventors is accepted where it is shown that one of the joint inventors is the sole inventor of the claim or claims under rejection.

The rejection is therefore maintained of record.

3. Claims 23, 24, 28, 29, 32, 33, 35, and 36 are newly rejected under 35 U.S.C. 112, first

Application/Control Number: 10/078,808

Art Unit: 1646

paragraph, because the specification, while enabling for the use of BMP-2, BMP-9, and other BMPs known to have effects on cartilage, does not reasonably provide enablement for all bone or cartilage inducing factors or all BMPs as broadly claimed. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

These claims are drawn to methods of use of all bone and cartilage inducing factors, or all BMPs. They thus require the use of a genus of molecules, bone and cartilage inducing factors, or BMPs that induce bone or cartilage. However, neither the instant specification nor the prior art provide guidance sufficient for the artisan to make and use this genus of factors. While many factors are know to affect bone and cartilage, Applicant has not provided any common characteristics by which the artisan could recognize individual members of this genus. No common structures or other defining features are provided. The art teaches that not even all member of the BMP family possess the required function. Valcourt et al., for example, found that BMP-2 and BMP-4 induced both chondrocytic and osteoblastic markers in a chondrocyte cell line, whereas BMP-12 (GDF-7) and BMP-13 (GDF-6) had minimal effect (p. 265, column 1). Thus, without further guidance as to the nature of the bone and cartilage forming molecules, including BMPs, that would be useful to induce chondrogenic characteristics in the cells, it would require undue experimentation for the artisan to practice the invention as broadly claimed.

4. Claims 23, 24, 28, 29, 32, 33, 35, and 36 are also newly rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter that was not described in the specification in such a way as to reasonably

convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

As stated above, Applicant has not described the characteristics of the bone and cartilage inducing factors, or of the members of the BMP family, that would be useful for inducing chondrogenesis and thus also for treating arthritis or injury. The structural and functional features required for the desired activity are not provided. Also as stated above, the art teaches that members of the BMP family have different effects on the characteristic features of cartilage, so the identification of a molecule as a BMP is not sufficient to identify it as an agent that could be used in the instant methods.

NO CLAIM IS ALLOWED.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet L. Andres whose telephone number is 571-272-0867. The examiner can normally be reached on Monday, Tuesday, Thursday, Friday, 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 571-272-0829. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/078,808

Art Unit: 1646

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Janet L. Andres, Ph.D. 20 June 2005

JANET ALTES PRIMATE ANGINER Page 5